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Edited by Jesus AvilaAbstract Here, we produced the C-terminal truncation variants
of mouse inducible heat shock protein 72 (Hsp72) to elucidate
the regulatory role of the C-terminal helical lid of Hsp70 for
substrate recognition. All of the truncation variants containing
the substrate binding domain bound a short-length peptide
substrate CLLLSAPRR. When a large mass reduced carb-
oxymethyl a-lactalbumin (RCMLA) as a substrate was used in
gel ﬁltration experiment, we observed the complex formation
only for the truncation variants containing the long a-helix C in
the helical lid. However, RCMLA binding occurred even for the
variants lacking a-helix C when their C-terminal region was
anchored onto a solid phase. Together with the ﬁnding that helix
C is involved in the self-association of Hsp70, our present data
suggest that the C-terminal region of Hsp70 modulates the
substrate recognition and its kinetics may be substrate-mass
dependent.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Heat shock protein (Hsp) 70 is one of the molecular chap-
erones that are expressed constitutively or in response to sev-
eral types of stress, including heat shock, oxidative stress,
glucose deprivation, and exposure to toxins and heavy metals
[1–4]. Hsp70s are known to assist a variety of cellular processes
such as protein folding, assembly and disassembly of multi-
meric proteins, protein translocation across membranes, pro-
tein degradation and signal transduction [2–4].
The molecular chaperone Hsp70 is basically composed of
three structural domains [5]. The N-terminal 44 kDa segment
that contains the adenosine nucleotide binding site displays a
weak intrinsic ATP-hydrolytic activity [6,7]. The structure of
this domain is similar to the structures of hexokinase and
actin [7–9]. The adjacent 18 kDa segment has been shown to
bind peptide substrates [10]. The X-ray crystallographic* Corresponding author. Fax: +81-774-33-3004 (or +81-774-38-3740).
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b-sandwich structure made up of eight b-strands and loops
[11]. The channel to which peptide substrates are bound is
covered with a compact lid-like structure made up of a-he-
lices that are followed by a disordered ﬂexible tail [11]. Re-
cently, Chou et al. [12] reported that the folding pattern of
a-helices in the lid structure of rat Hsc70 diﬀers from that of
DnaK. The region of DnaK in the lid structure is composed
of four helices, aB–aE, whereas the equivalent region of rat
Hsc70 adopts a helix-loop-helix conformation.
A variety of peptides and nascent polypeptide chains have
been shown to be substrates of the C-terminal peptide binding
domain of Hsp70 [13,14]. In general, Hsp70 preferentially
binds hydrophobic peptides. A minimum peptide length of
seven residues is required for optimal binding to BiP, the
ER-located Hsp70 [15]. It has been proposed that BiP prefer-
entially binds peptides containing hydrophobic residues in al-
ternating positions [16]. Hsp70 also forms a stable complex
with unfolded proteins, such as reduced carboxymethylated
a-lactalbumin (RCMLA), a thermally unstable mutant of
staphylococcal nuclease, and apocytochrome c [17–19]. DnaK
binding sites in protein sequences were found to occur statis-
tically in every 36 residues [20]. Using a leucine-rich octapep-
tide and RCMLA, Hu and Wang reported that the C-terminal
10 kDa fragment appears to play a role in complexing with
RCMLA [21]. However, it remains to be elucidated how the C-
terminal region of Hsp70 is involved in the recognition of
peptide substrates.
Here, using recombinant truncation variants that are se-
quentially lacking the individual helix and a ﬂexible tail of
mouse inducible Hsp72, we show the eﬀect of deletion of the
C-terminal domain on binding to two kinds of substrates with
diﬀerent peptide length.2. Materials and methods
2.1. Materials
ATP-Na2 (purity >98%), ATP-agarose (A-2767), and RCMLA were
purchased from Sigma. Acrylodan-peptide CLLLSAPRR (a-p5) was
synthesized at and purchased from Kurabo, BioMedical, Japan. The
antiserum against mouse Hsp70 (SPA-812) from StressGen Biotech-
nologies Corp. (Canada) and the HRP-conjugated monoclonal anti-
body against histidine-tag from Invitrogen (Carlsbad, CA, USA) were
used for detection of the recombinant variants. EZ-LinkTM sulfo-
NHS-LC-biotin (Pierce) was used to biotinylate the RCMLA protein.
A ﬂuorescein-EX labeling kit to ﬂuoresceinate proteins was from
Molecular Probe. Labeling of RCMLA was performed according to
the manufacturer’s protocol.blished by Elsevier B.V. All rights reserved.
382 M. Ohno et al. / FEBS Letters 576 (2004) 381–3862.2. Cloning, expression, and puriﬁcation of Hsp72 recombinant
variants
To express mouse Hsp72 and its C-terminal truncation variants,
d(1–615), d(1–562), d(1–543), and d(1–384), we introduced the corre-
sponding cDNA fragments into pET-20b(+) vector using NdeI and
XhoI sites (Novagen). Brieﬂy, the corresponding cDNA fragments
were ampliﬁed by PCR techniques using sets of speciﬁc primers and
the plasmid mhsp72-pcDNA, which contains the cDNA encoding the
entire sequence of mouse hsp72, as a template. 50-GCACGA-
GGGATCCATATGGCCAAGAACACGGCGATC-30 was used as
the forward primer in all cases. The reverse primers for the wild-type,
d(1–615), d(1–562), d(1–543), d(1–384) were 50-CAGCAGAGGCTC-
GAGATCCACCTCCTCGATGGT-30 for the full-length hsp72 with




PCR products were subcloned into the same restriction enzyme sites of
pET-20b(+). The resulting plasmids were suitable for expression of the
designed proteins with a histidine tag at their C-termini. After the
plasmids were introduced into Escherichia coli BL21(DE3), the bac-
teria harboring the constructed plasmids were grown in LB media for
protein expression. After isopropyl-b-D-thiogalactopyranoside induc-
tion for 4 h, bacterial extract containing the designed proteins pro-
duced were applied to a Ni–NTA agarose (Qiagen) column, which was
basically developed according to the manufacturer’s protocol. After
dialysis of the eluate against buﬀer A [20 mM HEPES, 20 mM KCl, 10
mM (NH4)2SO4, 5 mM MgSO4, 1 mM dithiothreitol, and 0.5 mM
phenylmethylsulfonyl ﬂuoride (pH 7.0)], the dialysate was applied to
ATP agarose (Sigma), which was developed according to the method
described by Schlossman et al. [22]. After extensive dialysis in the
presence of EDTA and a saturated concentration of ammonium sul-
fate to remove ATP, all samples were ﬁnally dialyzed against buﬀer B
[20 mM NaH2PO4, 150 mM KCl, and 3 mM 2-mercaptoethanol (pH
7.0)] and then stored at 4 C before use.
2.3. Size-exclusion chromatography
The molecular size and status of recombinant proteins was analyzed
by size-exclusion chromatography using a column of TSK gel
G2000SW (7.5 i.d. · 300 mm, TOSOH, Tokyo, Japan) that was
equilibrated with buﬀer C [20 mM NaH2PO4, 150 mM KCl (pH 6.5)].
The protein samples were incubated at 37 C for 30 min in buﬀer B in
advance and eluted with buﬀer C at a ﬂow rate of 0.5 mL/min.
The size-exclusion chromatography with a column of Superdex 200
HR 10/30 (Amersham Biosciences, Piscataway, NJ, USA) was used to
check complex formation of the truncation variants with the peptide a-
p5. The proteins were eluted with buﬀer C at a ﬂow rate of 0.5 mL/min
and monitored at the wavelength of 280 nm. The acrylodan-derived
ﬂuorescence was detected using a spectroﬂuorometric detector RF-550
(Shimadzu, Kyoto, Japan) at the excitation wavelength of 370 nm and
the emission wavelength of 520 nm.Fig. 1. Design of recombinant Hsp72 and its truncation variants. (A)
Shown is a schematic of the wild-type Hsp72 (residues 1–641) with the
boundaries indicated numerically. The lid region is not drawn to scale.
(B) SDS–PAGE of the puriﬁed truncation variants. Samples (1.5 lg
protein/lane) were electrophoresed on a 10% acrylamide gel and vi-
sualized by Coomassie Brilliant Blue staining: lane 1, molecular weight
marker; lane 2, wild-type Hsp72; lane 3, variant d(1–615); lane 4,
variant d(1–562); lane 5, variant d(1–543); lane 6, variant d(1–384).
(C), (D) Western blotting of the puriﬁed truncation variants (150 ng
protein/lane). Proteins were probed with polyclonal anti-Hsp72 anti-
body (C) and a monoclonal antibody against the histidine-repeat se-
quence (D): lanes 7 and 12, wild-type Hsp72; lanes 8 and 13, variant
d(1–615); lanes 9 and 14, variant d(1–562); lanes 10 and 15, variant
d(1–543); lanes 11 and 16, variant d(1–384).2.4. Analyses of the binding of recombinant variants to peptide
substrates
To measure complex formation of the recombinant proteins with the
peptide a-p5, the excitation wavelength was set at 370 nm and the
emission at 500 nm was recorded. The spectra of the peptide a-p5 or of
the a-p5–protein complexes were scanned from 430 to 610 nm. Reac-
tions were initiated by manually adding the peptide solution with a
microliter pipette to protein solution in a quartz cuvette and observed
at 25 C for 30 min. The ﬂuorescence spectral data were collected with
a ﬂuorescence spectrophotometer F-3000 (Hitachi, Japan).
FITC-labeled RCMLA was incubated at 37 C for 30 min with the
truncation variants at a molar ratio of 1:1 in the presence of buﬀer D
[20 mM Tris–HCl, 150 mM KCl, and 3 mM 2-mercaptoethanol (pH
7.4)]. The variant-RCMLA complex was loaded on a column of TSK
gel G3000SW (7.5 i.d. · 300 mm, TOSOH, Tokyo, Japan) that was
equilibrated with buﬀer C. The proteins eluted were monitored at the
wavelength of 280 nm and the FITC ﬂuorescence was detected using a
spectroﬂuorometric detector at the excitation wavelength of 492 nm
and the emission wavelength of 515 nm.
The truncation variants were mixed with Ni–NTA magnetic beads
(Qiagen) to immobilize the proteins through the C-terminal histidine-
tag sequence. After 5 min of incubation, the immobilized proteins were
incubated at 37 C for 30 min with biotinylated RCMLA at a molarratio of 1:1 in the presence of buﬀer E [10 mM NaH2PO4, 150 mM
KCl, 3 mM 2-mercaptoethanol, and 0.005% Tween 20 (pH 7.5)]. After
the incubation, the beads were washed twice with buﬀer E and then the
variant–RCMLA complex was eluted from the beads in the presence of
buﬀer F [50 mM NaH2PO4, 300 mM NaCl, 3 mM 2-mercaptoethanol,
250 mM imidazole, and 0.005% Tween 20 (pH 7.5)]. Eluted samples
were subjected to SDS–PAGE and blotted onto PVDF membranes to
detect the biotinylated RCMLA using a chemiluminescence system
(Amersham Biosciences). To check the ATP-dependent dissociation of
RCMLA substrate, the beads were treated at 37 C for 5 min in the
presence of 5 mM ATP and 10 mM MgCl2 before washing the beads
containing the variant–RCMLA complex.
2.5. CD measurement
CD spectra were recorded with a spectrometer (model J-720; Jasco,
Tokyo Japan) equipped with an interface and computer. Far-UV CD
spectrawere recorded at a protein concentration of 0.25mg/mLwith a 1-
mm cell at wavelengths from 250 to 195 nm. The unfolding transition
curves for the recombinant proteins were obtained by measuring the
ellipticity at 222 nm in a 1-mm cell at a protein concentration of 0.25mg/
mL in the presence of buﬀer B. The temperature was increased from 25
to 85 C at a rate of 1.0 C/min for the heat-denaturation process. The
measured ellipticities were corrected for the temperatures monitored
with a thermocouple (type SK-2000MC; Sato Keiryoki Mfg. Co., Ltd.,
Japan) and a ﬂexible probe inserted directly into the 1-mm cell.3. Results
3.1. Characterization of the recombinant truncation variants
The crystal structure of rat Hsc70 shows that its 10-kDa
subdomain adopts a helix-loop-helix fold and that this con-
Fig. 2. Far-UV spectra of the recombinant proteins. Curve 1, Oval-
bumin that had completely unfolded in the presence of 6 M guanidium
hydrochloride; curve 2, wild-type Hsp72; curve 3, variant d(1–615);
curve 4, variant d(1–562); curve 5, variant d(1–543); curve 6, variant
d(1–384).
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DnaK, the bacterial homolog of Hsc70 [12]. Considering the
data of Chou et al. showing that a-helix C corresponds to
amino acid residues 564–610 in mouse inducible Hsp72, we
designed recombinant variants that sequentially deleted the
individual helices and the ﬂexible tail (Fig. 1A). The variants
d(1-615) and d(1–562) lack the ﬂexible tail at the extreme C-
terminus and the entire a-helix C, respectively. The variant
d(1–543) was constructed as a protein containing the mini-
mum unit of the substrate binding domain according to the
data of Wang et al. [10]. The SDS–PAGE patterns showed
that the puriﬁed proteins had the expected molecular sizes
with purity over 98% (Fig. 1B). Western blotting patterns
revealed that every product was reactive with the antiserum
against Hsp70 and had a precise sequence at the C-terminus,
conﬁrming the structural integrity of the Hsp70 entity
(Fig. 1C and D).
CD spectroscopy showed signiﬁcant secondary structure in
the truncation variants. Every variant showed signiﬁcant andFig. 3. Gel ﬁltration analysis of the recombinant proteins. Gel ﬁltration chrom
shown for the wild-type Hsp72 (A), variant d(1–615) (B), and variant d(1–5intrinsic secondary structure (Fig. 2). Especially, the proﬁle of
the wild-type protein had peaks at 208 nm and 222 nm, re-
ﬂecting signiﬁcant content of a-helix, whereas the proﬁle of
d(1–543), which lacks a few a-helices in the C-terminal 10-kDa
subdomain, had the peak at 215 nm, suggesting the presence of
signiﬁcant b-sheet structure in the substrate binding domain.
3.2. Self-association of the recombinant truncation variants
Since several reports have shown that the C-terminal portion
of Hsp70 molecules could be involved in self-association
[12,23–25], the truncation variants were subjected to size-
exclusion chromatography (Fig. 3). The wild-type recombinant
and d(1–615) variant were found to exist as monomer, dimer
and oligomer, although there may be diﬀerences in the pro-
portions of self-association (Fig. 3A and B). On the other
hand, variant d(1–562) predominantly existed as the monomer
(Fig. 3C). The recombinant variants d(1–543) and d(1–384)
were also monomeric (data not shown). This suggests that the
long a-helix C at the C-terminus is responsible for self-
association of Hsp70 molecules.
3.3. Thermal stability monitored by far-UV CD of the
truncation variants
Fig. 4 shows the changes in the ellipticity at 222 nm of the
truncation variants as a function of temperature in the range of
30–80 C. The wild-type hsp72 (Fig. 4A) and d(1–615) variant
(Fig. 4B) underwent a small cooperative conformational
change in the vicinity of 42 C followed by a second and less
cooperative transition in the temperature range of 60–80 C.
Abrupt transition took place around the temperature of 42 C
for two truncation variants, d(1–562) and d(1–543) (Fig. 4C
and D). In the presence of Mg2þ/ATP, however, the stability of
all recombinant proteins was increased so that they were
substantially stable at the temperature below 55 C. Thus, the
C-terminal truncation did not cause a marked decrease in
thermal stability.
3.4. Molecular interactions between the truncation variants and
various substrate peptides
A number of short peptides have been reported so far to
bind to Hsp70, with Kd values ranging from 1 to 20 lM
[13,16,26,27]. Unfolded proteins such as RCMLA and aatography was performed as described in Section 2. Elution proﬁles are
62) (C).
Fig. 5. Binding of acrylodan-CLLLSAPRR (a-p5) peptide to the re-
combinant proteins. Fluorescence emission spectra of protein-bound
a-p5 were recorded under the conditions described in Section 2. The
emission at 500 nm was compared as the relative ﬂuorescence.
Fig. 4. Thermal stability monitored by far-UV CD of the truncation
variants. Shown is the observed ellipticity at 222 nm that changes as a
function of temperature. The temperature was increased from 25 C to
85 C at a rate of 1.0 C/min for the heat-denaturation of the wild-type
(A), variant d(1–615) (B), variant d(1–562) (C), and variant d(1–543)
(D).
Fig. 6. Gel ﬁltration analysis of the recombinant proteins complexed
with a-p5 peptide. Gel ﬁltration chromatography was performed as
described in Section 2. From upper line, elution proﬁles are shown for
the wild-type Hsp72, variant d(1–615), variant d(1–562), variant d(1–
543), and variant d(1–384).
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known to form complexes with Hsp70 [17–19]. We investigated
if the types of peptide substrate may aﬀect the binding prop-
erties of Hsp72. The peptide a-p5 is a representative substrate
for E. coli Hsp70 DnaK [28–30]. On binding to DnaK under
our experimental conditions, the ﬂuorescence spectrum of a-p5
underwent a blue shift of emission maximum from 526 to 513
nm, depending on the concentration of DnaK. The ﬂuores-
cence intensity of a-p5 at 500 nm in the presence of 10 lM
DnaK concomitantly increased to 370% of that of the un-
bound ligand (data not shown). When the relative ﬂuorescence
of a-p5 as a measure of peptide binding was compared among
the truncation variants at the concentration of 10 lM (Fig. 5),
the variants containing substrate-binding domain displayed
signiﬁcant binding of the peptide a-p5. Binding of the peptide
a-p5 by the truncation variants including d(1–562) was clearly
detected by the size-exclusion chromatography as shown in
Fig. 6. We observed the decreased ﬂuorescence intensity in
both experiments by sequentially deleting the C-terminal re-
gion of Hsp72. This may result from increased quenching that
is expected as the lid structure is deleted. However, these data
suggest that the truncation variants intrinsically retain the
ability to bind peptide substrate.
When the formation of substrate–Hsp72 complex was ex-
amined using an unfolded protein RCMLA instead of the
nonapeptide a-p5, FITC-labeled RCMLA bound the wild-type
Hsp72 and variant d(1–615) (Fig. 7A and B). Addition of
Mg2þ-ATP to the reaction mixture caused dissociation of the
RCMLA substrate from Hsp72 complexes (Fig. 7D and E),
suggesting that the substrate binding was intrinsically ATP-
dependent. In this gel ﬁltration experiment, however, we couldnot observe the peak showing the complex of other shorter
truncation variants such as variant d(1–562) with RCMLA
(Fig. 7C). To address if protein stability can aﬀect the binding
property, we examined the binding of d(1–562) variant with
RCMLA in the presence of Mg2þ/ADP. No detectable peak
appeared under this condition, as shown in Fig. 7F.
Then, we examined binding property of the truncation
variants to RCMLA substrate under the condition where they
were immobilized on the Ni2þ–NTA magnetic beads through
Fig. 7. Binding of FITC-labeled RCMLA to the recombinant proteins
free in solution. Gel ﬁltration chromatography was performed as de-
scribed in Section 2. The upper three panels show the elution proﬁles of
FITC-labeled RCMLA that was mixed with wild-type Hsp72 (A),
variant d(1–615) (B), and variant d(1–562) (C). The lower three panels
show the elution proﬁles of the wild-type Hsp72 (D) and d(1–615)
variant (E) after incubation in the presence of Mg2þ/ATP, and
d(1–562) variant after incubation in the presence of Mg2þ/ADP (F).
Elution positions of the complex RCMLA-Hsp72 and free RCMLA
are shown by closed and open triangles, respectively.
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shown in Fig. 8, the variants except for d(1–384) showed nu-
cleotide-dependent formation of the Hsp-RCMLA complexes,Fig. 8. Binding of biotinylated RCMLA to the recombinant proteins
anchored onto Ni-NTA solid phase. Biotinylated RCMLA that had
bound to wild-type Hsp72 and its truncation variants was analyzed by
SDS–PAGE and visualized using the ECL Western blotting analysis
system (Amersham) with HRP-conjugated streptavidin. No RCMLA
was detected in the reaction without Hsp72 (lane 1). The wild-type
Hsp72 (lanes 2–4), variant d(1–615) (lanes 5–7), variant d(1–562) (lanes
8–10), variant d(1–543) (lanes 11–13), or variant d(1–384) (lanes 14–16)
was incubated in the absence (lanes 2, 5, 8, 11, and 14) or the presence
(lanes 3, 4, 6, 7, 9, 10, 12, 13, 15, and 16) of biotinylated RCMLA. The
reaction mixtures were treated with ATP to dissociate the Hsp70-
RCMLA complex (lanes 4, 7, 10, 13, and 16).although there may have been diﬀerences in the binding ca-
pacity. Interestingly, unlike the case of the peptide a-p5, the
deletion of the ﬂexible tail portion greatly reduced the ability
of the truncation variants to bind to RCMLA.4. Discussion
In the present study, we showed that the long a-helix C in
the helical lid and the following ﬂexible region of Hsp72 in-
ﬂuence the recognition of a large mass substrate. The kinetics
for substrate release may be substrate-mass dependent. Also,
helix C was shown to be required for self-association of Hsp72.
The truncation variants containing the substrate-binding
domain were shown to bind a short-length peptide a-p5 (see
Figs. 5 and 6). Taking into account quenching eﬀect, the ob-
served decrease in ﬂuorescence does not always reﬂect a de-
crease in the amount of bound peptide. However, we
qualitatively showed that residues 385–543 in the variants we
produced can form a functional subdomain that potentially
has binding ability for the substrate peptide. This observation
is compatible with the report of Wang et al. [10].
When RCMLA was used as a large mass substrate, we could
not detect the peak showing the complex of the variant d(1–
562) with RCMLA in the size-exclusion chromatography ex-
periment. In contrast, d(1–562) variant was shown to bind
RCMLA when the variant was immobilized on the Ni2þ–NTA
magnetic beads. This discrepancy may be explained by the
following possible reasons. First, the b-sandwich substrate-
binding domain itself may have lost the structural stability
needed for recognition of RCMLA polypeptide because, in
general, the truncation causes the decrease in protein stability
to change physical properties. However, a marked decrease in
thermal stability by the C-terminal truncation was not ob-
served as shown in Fig. 4. There was no peak showing the
complex of d(1–562) variant with RCMLA even though the
stability of the variant was increased in the presence of Mg2þ/
ADP. These data allow us to rule out the ﬁrst possibility.
Second, d(1–562) variant could bind RCMLA, but the oﬀ-
rate has increased compared to the wild-type. RCMLA might
dissociate from the variant during the transit time down the
column of gel ﬁltration, because helix D in DnaK was shown
to be essential for long-lived DnaK-peptide complexes and the
oﬀ-rate was markedly increased when helix D is deleted [31].
The region equivalent to helix D of DnaK is included in the
sequence between 563 and 615 residues of mouse Hsp72.
Taking into account that the complex of d(1–562) variant with
a-p5 peptide was clearly detected in the column experiment as
shown in Fig. 6, this observation raises the possibility that the
increase in oﬀ-rate can be substrate-mass dependent. To ad-
dress this problem, we should require a larger set of quanti-
tative experiments with peptide libraries showing diversity in
sequence and mass.
An individual helix in the C-terminus of DnaK discretely
coordinates the functional structure of the helical lid of DnaK.
Helix D of DnaK is necessary and suﬃcient to create the
protective lid structure when a substrate peptide is added. In
the absence of peptide, helix E promotes the formation of the
antiparallel helical bundle composed of the B to D helices and
prevents internal ligand formation [31]. Wang and colleagues
showed that internal ligand formation, i.e., self-binding, occurs
in the region of DnaK which contains the b-sandwich sub-
386 M. Ohno et al. / FEBS Letters 576 (2004) 381–386strate-binding domain plus the lid helices aA and aB [32]. This
self-binding results from the fact that leucine residue 543 in
helix B is tightly held in a deep hydrophobic pocket within the
substrate-binding site, leading to stabilization of substrate-
binding domain. Similarly, in rat Hsc70, leucine residue 542
was observed to intramolecularly interact with the hydropho-
bic groove of the substrate-binding domain by salt-bridge
formation [33]. Three discrete helices C-E in DnaK are
equivalent to the long a-helix C in the helix-loop-helix fold of
rat Hsc70 [12]. Assuming that the C-terminal structure of
mouse inducible Hsp72 is similar to that of the rat Hsc70
homolog, the region around the end of helix B0 of variant d(1–
562) is presumed to cause internal ligand formation that re-
tards RCMLA recognition. The long helix C of mouse Hsp72,
which contains the equivalent portion to helices D and E of
DnaK, may regulate internal ligand formation by helix B0.
According to the substrate mass, therefore, helix C may play a
role in modulating the oﬀ-rate for substrate binding.
Another interesting result in this study is that deletion of the
ﬂexible tail results in decreased RCMLA binding (see Fig. 8).
Recently, Demand et al. reported that the C-terminal 10-kDa
domain could interact with Hdj-1/Hsp40 [34]. The EEVD
motif at the extreme C-terminus of human Hsp70, which is
conserved among many species, is known to be important for
its peptide binding activity and ATPase activity because mu-
tation of the EEVD sequence abolishes chaperone activity
[35,36]. The reduction of RCMLA binding to d(1–615) variant,
compared to the wild-type Hsp72, might result from the de-
letion of this EEVD motif in the variants. Deletion of the lid of
DnaK increases the kinetics of ATP-triggered peptide release
[37]. The ﬂexible tail and helix E of DnaK modulate the ki-
netics of ATP binding [31]. Taken together, the C-terminal tail
could work in concert with the nucleotide-binding domain to
control the kinetics for binding of a large mass substrate.
Additionally, our present data clearly showed that helix C
dictates the chaperone self-association (see Fig. 4) and are thus
compatible with the results reported by Chou et al. [12]. Under
certain conditions Hsp70 proteins are known to exist as olig-
omers, which are converted to monomers in the presence of
peptide substrates or ATP [17,38]. That oligomers also form in
vivo has been suggested by genetic data obtained from studies
of dominant hsp70 mutations and intergenic complementation
experiments between hsp70 mutants [39,40].
Considering that the C-terminal region of Hsp70 may
modulate the kinetics of the substrate recognition according to
the substrate-mass speciﬁc oﬀ-rate, we speculate that the he-
lical lid region of Hsp70 may signiﬁcantly regulate intracellular
protein synthesis as the chain length of a polypeptide being
synthesized increases. Further investigations will be needed in
the future to elucidate the biological function of the C-terminal
region of the Hsp70 family in vivo.
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